A groundbreaking clinical trial has revealed that the drug daraxonrasib could potentially double the survival rate of patients with advanced pancreatic cancer. The study, published in the New England Journal of Medicine, offers new hope for a disease that is often diagnosed at a late stage when surgical removal is not possible.
New Hope for Pancreatic Cancer Patients
Pancreatic cancer is notoriously difficult to treat, with most patients discovering the disease after it has already spread. Chemotherapy has been the primary treatment option, but very few patients survive beyond one year of diagnosis. More than 90% of patients have genetic mutations called KRAS driving their cancer, which were long considered untreatable.
However, a class of drugs called RAS inhibitors has emerged in the last decade as effective options to target mutated genes like KRAS. These drugs can "turn off" mutated RAS genes, putting them into a dormant state. Daraxonrasib is one such RAS inhibitor therapy.
Clinical Trial Results
In the early-phase trial, 38 patients with pancreatic adenocarcinomas received a daily 300 milligram dose of daraxonrasib. Their overall survival rate increased to 15.6 months, compared to standard chemotherapy, which typically improves survival for only up to 6.7 months.
"This trial provides a really strong signal that this targeted therapy has the potential to extend the overall survival of these patients," said David Hong, an author of the study. "We saw rapid and durable responses, and the manageable overall safety profile supports the ongoing evaluation of daraxonrasib."
Side Effects and Future Research
Some patients experienced side effects, including rash, diarrhoea, throat inflammation, and fatigue, but no one had to discontinue treatment due to these effects. Researchers are now studying the drug's effectiveness further in a larger, ongoing clinical trial.
"If supported by data from future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer," said Brian Wolpin, another author of the study. "If this drug proves effective in larger clinical trials, it would signify a substantial shift in how this disease is treated."
The final analysis of the trial will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on 31 May. "Although much work remains to be done, it genuinely feels like a new day is dawning for pancreatic cancer treatment, with daraxonrasib potentially serving as the first of a set of new medicines that broadly target mutant RAS," Dr Wolpin concluded.
